Clinical Trial Update: Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T [Phase 2]

View source ↗

Summary

Phase 2 trial investigating everolimus for disfiguring cutaneous lesions in Neurofibromatosis Type 1 has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Neurofibromatosis 1 | Phase 2 | Status: COMPLETED | Results posted: 2017-06-06